Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Cash from Financing Activities: 2019-2025

Historic Cash from Financing Activities for Avidity Biosciences (RNA) over the last 6 years, with Sep 2025 value amounting to $850.4 million.

  • Avidity Biosciences' Cash from Financing Activities rose 148.31% to $850.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $869.8 million, marking a year-over-year decrease of 28.15%. This contributed to the annual value of $1.2 billion for FY2024, which is 1170.30% up from last year.
  • Per Avidity Biosciences' latest filing, its Cash from Financing Activities stood at $850.4 million for Q3 2025, which was up 22,438.19% from $3.8 million recorded in Q2 2025.
  • Over the past 5 years, Avidity Biosciences' Cash from Financing Activities peaked at $850.4 million during Q3 2025, and registered a low of $17,000 during Q1 2021.
  • Over the past 3 years, Avidity Biosciences' median Cash from Financing Activities value was $31.9 million (recorded in 2023), while the average stood at $194.8 million.
  • Per our database at Business Quant, Avidity Biosciences' Cash from Financing Activities crashed by 99.90% in 2023 and then soared by 856,060.00% in 2024.
  • Avidity Biosciences' Cash from Financing Activities (Quarterly) stood at $20.7 million in 2021, then soared by 1,076.28% to $243.7 million in 2022, then tumbled by 86.91% to $31.9 million in 2023, then tumbled by 56.97% to $13.7 million in 2024, then spiked by 148.31% to $850.4 million in 2025.
  • Its Cash from Financing Activities was $850.4 million in Q3 2025, compared to $3.8 million in Q2 2025 and $1.9 million in Q1 2025.